Praxis Precision Medicines (PRAX) Common Equity (2019 - 2026)

Praxis Precision Medicines' Common Equity history runs 8 years deep, the most recent figure standing at $1.4 billion for Q1 2026.

• On a quarterly basis, Common Equity rose 221.02% year-over-year to $1.4 billion in Q1 2026; TTM through Mar 2026 was $1.4 billion, a 221.02% increase from a year earlier, with the FY2025 full-year figure at $878.1 million, up 97.13% from the prior year.
• Common Equity improved to $1.4 billion in Q1 2026 per PRAX's latest filing, from $878.1 million in the prior quarter.
• Across five years, Common Equity topped out at $1.4 billion in Q1 2026 and bottomed at $64.5 million in Q1 2023.
• The 5-year median for Common Equity is $229.7 million (2024), against an average of $340.6 million.
• Across the five-year window, Common Equity slumped 69.66% in 2022 and jumped 539.38% in 2024, its largest moves.
• Year by year, Common Equity stood at $76.1 million in 2022, then slipped by 8.46% to $69.7 million in 2023, then soared by 539.38% to $445.4 million in 2024, then surged by 97.13% to $878.1 million in 2025, then soared by 60.56% to $1.4 billion in 2026.
• Per Business Quant, the three latest PRAX Common Equity figures stand at $1.4 billion (Q1 2026), $878.1 million (Q4 2025), and $343.5 million (Q3 2025).